Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01185-7
Affiliations:
5
Authors:
12
Go to article
Institutions Authors Share
Novo Nordisk, Denmark
9.000000
 0.75
Novo Nordisk India, India
1.000000
 0.08
Yale University, United States of America (USA)
1.000000
 0.08
ICON - USA, United States of America (USA)
1.000000
 0.08
Interested in Pharmacology and Pharmaceutical Sciences?